rino
rappuoli
vaccin
remain
costeffect
public
health
intervent
clean
water
benefit
impress
outweigh
cost
effort
need
fulfil
steadili
grow
demand
nextgener
novel
vaccin
design
emerg
pathogen
new
indic
realiz
sustain
busi
model
vaccin
develop
fasttrack
strengthen
intern
collabor
continu
innov
technolog
acceler
design
develop
manufactur
howev
process
support
balanc
project
portfolio
manag
sustain
vaccin
procur
strategi
differ
type
market
collect
allow
gradual
shift
streamlin
profit
vaccin
product
significantli
contribut
worldwid
effort
shape
global
health
vaccin
remain
one
costeffect
public
health
intervent
address
worldwid
health
econom
burden
associ
infecti
diseas
inde
everi
us
spent
vaccin
diseas
associ
antigen
lowincom
middleincom
countri
lmic
estim
return
invest
societi
us
due
direct
save
healthcar
increas
product
nearli
three
time
higher
us
broader
econom
social
benefit
consid
broader
benefit
could
amount
stagger
us
billion
countri
support
global
allianc
vaccin
immun
gavi
publicpriv
partnership
ppp
involv
amongst
other
un
vaccin
industri
bill
melinda
gate
foundat
bmgf
due
higher
diseas
burden
limit
medic
infrastructur
gain
introduc
vaccin
lmic
greater
higherincom
countri
hic
gain
larg
determin
competit
differ
health
option
offer
global
demand
vaccin
grow
due
host
factor
global
popul
growth
futur
implement
newli
licens
advancedstag
vaccin
healthcar
system
ongo
global
immun
campaign
latter
illustr
gavi
aim
reach
addit
million
children
routin
childhood
vaccin
also
pressur
mount
deliv
improv
new
vaccin
challeng
infecti
diseas
eg
tuberculosi
hivaid
new
zoonot
pathogen
therapeut
vaccin
noncommunic
chronic
diseas
cancer
neurodegen
diseas
also
need
address
scourg
antibioticresist
bacteria
vari
vaccin
need
across
person
lifespan
vaccin
lifecycl
manag
support
lifecours
immun
meet
increas
demand
continu
quest
innov
vaccin
design
manufactur
technolog
tradit
multiphas
vaccin
develop
process
typic
progress
period
vaccin
discoveri
advanc
clinic
develop
phase
efficaci
trial
requir
invest
us
billion
combin
slim
probabl
candid
enter
market
neg
impact
number
invest
vaccin
manufactur
contribut
current
product
gap
vaccin
develop
select
criteria
support
priorit
vaccin
project
must
therefor
increasingli
stringent
discuss
key
consider
decisionmak
process
vaccin
manufactur
perspect
medic
need
key
factor
project
priorit
illustr
spur
develop
vaccin
global
emerg
threat
pose
clostridium
difficil
infect
acceler
clinic
develop
period
devast
ebola
crisi
west
africa
vaccin
could
shorten
less
year
prevail
busi
model
key
guid
criteria
technic
feasibl
well
expect
return
invest
latter
larg
determin
competit
landscap
analys
depend
econom
develop
statu
market
question
figur
nurtur
sustain
r
process
manufactur
busi
strategi
strive
maintain
project
portfolio
balanc
project
offer
solid
busi
case
higherrisk
longerterm
andor
lowerfeas
project
consider
financi
risk
inher
latter
categori
combin
press
immedi
need
expect
futur
medic
need
prompt
industri
seek
strateg
fund
partner
govern
andor
nonprofit
intern
vaccin
foundat
inde
nearli
everi
vaccin
avail
resourcepoor
set
today
develop
combin
public
privat
effort
underpin
sustain
vaccin
develop
collabor
funnel
guid
criteria
vaccin
project
priorit
first
unmet
medic
need
support
healtheconom
epidemiolog
epi
evalu
second
technic
feasibl
often
benefit
partnership
academia
acad
third
sustain
develop
depend
avail
fund
partner
collabor
develop
well
competit
landscap
comp
econom
develop
statu
market
vaccin
intend
market
develop
vaccin
market
includ
highincom
countri
often
predominantli
industryfund
trial
evalu
vaccin
predominantli
lowtomiddleincom
market
prepandem
vaccin
typic
cofund
publicpriv
partnership
includ
industri
govern
intern
nongovernment
organ
bar
red
blue
bar
indic
develop
stage
typic
benefit
involvementsupport
academia
intern
fund
organ
respect
academ
partner
mostli
contribut
provid
immunolog
insight
late
preclin
phase
clinic
phase
fund
partner
provid
support
throughout
whole
process
includ
licens
lic
phase
postlicens
phase
compris
vaccin
manufactur
manu
implement
implement
exampl
suppli
chain
manag
support
provid
publicpriv
partnership
mvaccin
postmarket
phase
studi
monitor
vaccin
usag
advers
effect
pharmacovigil
longterm
immun
typic
industryfund
red
arrow
bar
indic
technolog
use
guid
antigen
discoveri
andor
vaccin
design
revers
vaccinolog
deliveri
adjuv
platform
technolog
system
biolog
data
often
gener
industryacadem
partnership
guid
discoveri
phase
well
later
clinic
phase
support
adapt
trial
design
expedit
progress
phase
clinic
evalu
final
strategi
manag
sustain
procur
new
vaccin
tier
price
polici
also
majorli
drive
vaccin
develop
process
criterion
technic
feasibl
solid
understand
human
immunopatholog
point
academ
partnership
deliv
critic
knowhow
contribut
particularli
earli
clinic
develop
stage
ultim
vaccin
develop
also
driven
strategi
accomplish
sustain
procur
vaccin
tier
price
polici
next
examin
import
collabor
develop
differ
market
scenario
key
technolog
advanc
vaccinolog
support
first
market
scenario
involv
develop
vaccin
high
technic
feasibl
target
unmet
medic
need
least
partial
identifi
develop
portion
world
vaccin
gener
expect
larg
market
potenti
favor
return
invest
often
develop
minimum
extern
fund
prime
exampl
quadrival
influenza
vaccin
qiv
recommend
sinc
meningococcu
b
vaccin
recent
licens
subunit
herp
zoster
vaccin
hzsu
indic
prevent
shingl
person
age
year
vaccin
expect
translat
consider
benefit
societi
consid
consider
burden
worldwid
exampl
us
trillionyear
alzheim
diseas
develop
therapeut
vaccin
chronic
disord
neurodegen
diseas
cancer
would
commerci
appeal
yet
given
low
technic
feasibl
lack
knowledg
surround
constitut
protect
respons
develop
depriorit
major
manufactur
priorit
sever
biotech
compani
afford
take
higher
risk
groundwork
laid
intern
ppp
human
vaccin
project
european
innov
medicin
initi
imi
consortium
biovacsaf
aim
provid
insight
human
immun
requir
success
vaccin
may
break
technic
impass
least
area
second
scenario
major
public
health
threat
present
primarili
limit
commerci
market
case
hivaid
tuberculosi
malaria
infect
major
diseas
incomplet
knowledg
immunopathogenesi
mechan
natur
acquir
immun
amount
weak
busi
case
vaccin
develop
import
vaccin
target
diseas
develop
collabor
framework
prequalif
supran
organ
fourdos
vial
present
pneumococc
vaccin
recent
award
make
vaccin
elig
procur
un
agenc
provid
earli
return
invest
tier
price
also
support
develop
new
vaccin
use
profit
made
higher
price
hic
market
approach
follow
mani
childhood
vaccin
world
first
malaria
vaccin
rt
develop
ppp
includ
walter
reed
armi
institut
research
subsequ
path
malaria
vaccin
initi
mvi
bmgf
support
vaccin
donat
industri
mvi
vaccin
enter
pilot
implement
subsaharan
africa
coordin
fund
multipl
supran
organ
theori
postmarket
access
vaccin
enhanc
set
price
afford
lmic
expect
cover
manufactur
cost
well
small
return
reinvest
r
nextgener
malaria
vaccin
vaccin
tropic
diseas
practic
howev
realiz
sustain
postmarket
phase
procur
rt
still
challeng
due
absenc
sustain
market
vaccin
furthermor
aerasfund
collabor
academ
support
indepth
cellular
immun
assess
yield
tuberculosi
candid
vaccin
first
result
phase
efficaci
trial
expect
collabor
develop
also
brought
licens
dengu
vaccin
though
recent
safeti
concern
pose
major
setback
rollout
well
sever
shigella
candid
vaccin
particularli
import
combat
high
shigellosi
burden
infant
lmic
set
though
establish
correl
protect
exist
shigella
vaccin
develop
facilit
gener
accept
immunolog
associ
protect
two
promis
approach
alreadi
evalu
phase
studi
includ
bioconjug
flexneri
vaccin
support
wellcom
trust
monoval
sonnei
vaccin
base
geneticallyderiv
outer
membran
vesicl
shigella
gener
use
gener
modul
membran
antigen
gmma
technolog
latter
vaccin
develop
fund
european
commiss
program
addit
sever
multival
shigella
vaccin
earli
develop
third
categori
vaccin
target
zoonot
pathogen
pandem
potenti
pose
immedi
threat
vaccin
gener
lack
market
incent
purpos
pandem
prepared
pathogen
necessit
continu
surveil
human
anim
also
intensifi
develop
prepandem
vaccin
interoutbreak
period
beyond
recent
outbreak
pandem
influenza
ebola
zika
virus
list
diseas
outbreak
potenti
yet
possibl
except
pandem
influenza
vaccin
industri
alon
deliv
resourc
need
world
vaccin
suppli
therefor
new
globallyfund
ppp
task
prepandem
vaccin
develop
cepi
found
industri
wellcom
trust
bmgf
sever
nation
govern
initi
target
three
virus
prioriti
list
ie
middl
east
respiratori
syndrom
coronaviru
lassa
nipah
virus
addit
initi
propos
bioprepared
organ
focu
develop
util
vaccin
platform
technolog
sustain
suppli
price
procur
vaccin
address
yet
platform
technolog
critic
overcom
bottleneck
manufactur
discuss
technic
feasibl
fasttrack
design
develop
manufactur
multipl
innov
tool
technolog
origin
advanc
virolog
genet
structur
biolog
biotechnolog
avail
support
priorit
base
technic
feasibl
throughout
whole
develop
spectrum
antigen
discoveri
design
transform
novel
bioinformat
technolog
wholegenom
proteom
data
current
avail
mani
pathogen
exampl
identif
new
antigen
revolution
revers
vaccinolog
genomewid
sequenc
pathogen
scour
conserv
surfaceexpress
protein
complement
confirm
surfac
locat
vitro
subsequ
preclin
immunogen
evalu
combin
immunogen
led
develop
sever
broadli
protect
bacteri
viral
candid
vaccin
recent
shigella
candid
vaccin
licens
vaccin
serogroup
b
meningococcu
structur
biolog
deliv
insight
pathogen
entri
process
lead
design
rsv
antigen
niaid
compris
fusion
glycoprotein
stabil
prefus
trimer
conform
pref
conform
contain
highli
neutralizationsensit
epitop
antigen
site
preclin
evalu
show
vaccin
boost
preexist
rsv
neutral
respons
adjuv
enhanc
immunogen
may
particularli
relev
vaccin
target
elderli
adjuv
nonadjuv
vaccin
current
phase
trial
differ
antigen
version
headonli
version
preclin
evalu
need
univers
broadli
protect
vaccin
gener
immun
toward
highli
conserv
epitop
particularli
evid
vaccin
season
influenza
viru
frequent
chang
surfac
protein
necessit
annual
vaccin
reformul
pandem
strain
part
pandem
prepared
strategi
facilit
innov
structurebas
design
decadelong
effort
result
influenza
vaccin
candid
target
extracellular
domain
protein
conserv
region
domain
conserv
stalk
domain
particularli
latter
approach
appear
promis
season
pandem
purpos
given
upon
exposur
new
strain
immun
respons
prefer
direct
conserv
epitop
stalk
sever
avenu
explor
one
take
advantag
current
manufactur
process
entail
repeat
vaccin
construct
express
chimer
ha
subunit
conserv
stalk
domain
differ
exot
ha
head
never
encount
human
natur
condit
combin
adjuv
system
regimen
shown
preclin
model
induc
antistalk
igg
antibodi
well
antina
antibodi
may
also
contribut
protect
anoth
approach
includ
vaccin
base
headless
ha
immunogen
construct
remov
glycanmask
ha
head
domain
still
preclin
phase
adjuv
essenti
compon
mani
vaccin
use
enhanc
immun
antigen
particularli
import
popul
reduc
immun
respons
includ
instanc
hyporespons
vaccin
andor
popul
pathogen
abil
also
serv
increas
viabil
potenti
promis
vaccin
approach
recombin
protein
vaccin
allow
antigen
dosespar
streamlin
product
overcom
limit
manufactur
capabl
instanc
use
higher
antigen
dose
improv
efficaci
season
influenza
vaccin
elderli
season
vaccin
contain
oilinwat
adjuv
shown
efficaci
agegroup
standard
dose
least
certain
strain
broaden
bcell
repertoir
adjuv
also
extend
protect
coverag
monoval
pandem
influenza
vaccin
continu
effort
made
unravel
mode
action
differ
adjuv
thu
opportun
maxim
potenti
use
new
vaccin
evalu
innat
immun
induc
sever
adjuv
alum
highlight
role
ifnsign
pathway
activ
enhanc
adapt
immun
induc
research
use
system
biolog
approach
perform
use
candid
malaria
tuberculosi
hiv
vaccin
well
licens
hzsu
vaccin
effect
eggbas
vaccin
product
current
use
major
season
tivqiv
pandem
influenza
vaccin
drawback
less
amen
respons
surg
vaccin
need
pandem
cellcultur
manufactur
use
licens
pandem
influenza
vaccin
gener
faster
control
process
though
obstacl
celllin
scaleup
still
need
address
furthermor
need
new
highperform
vaccin
platform
prompt
develop
nucleic
acidbas
technolog
viral
vector
plasmid
dna
convent
rna
selfamplifi
rna
sam
abl
elicit
broadli
protect
robust
cellmedi
humor
immun
respons
sinc
express
vaccin
antigen
occur
situ
gener
rna
sam
vaccin
proven
potent
plasmid
dna
vaccin
product
purif
costeffect
rel
versatil
readili
transfer
differ
viral
target
besid
influenza
vaccin
rna
sam
vaccin
target
sever
pathogen
hiv
rsv
evalu
shown
confer
protect
anim
model
vaccin
includ
influenza
rabi
also
test
clinic
trial
promis
yet
satisfactori
result
underli
mechan
action
saminduc
immun
particularli
respect
earli
innat
immun
fulli
known
may
elucid
first
clinic
evalu
sam
vaccin
could
occur
take
time
vaccin
gener
compar
sam
technolog
viral
vector
vsv
mva
simian
adenoviru
vector
repres
technic
establish
vehicl
vaccin
deliveri
prime
exampl
replicationincompet
speci
c
chimpanzeederiv
adenoviru
chad
vector
use
ebola
vaccin
recent
rsv
pref
vaccin
current
pediatr
phase
trial
attract
chad
technolog
platform
lie
abil
vector
gener
potent
antigenspecif
tcell
humor
respons
reduc
risk
neutral
human
sera
due
neglig
seropreval
human
system
biolog
potenti
chang
vaccin
develop
provid
inform
character
transcript
cellular
signatur
vaccineinduc
respons
use
increas
knowledg
mechan
protect
pathogenesi
challeng
diseas
hiv
aid
tuberculosi
integr
molecular
pathway
data
gener
one
sever
omic
technolog
molecular
correl
earli
immunogen
protect
identifi
import
vaccin
includ
yellow
fever
vaccin
adjuv
influenza
vaccin
rt
malaria
vaccin
omic
approach
also
allow
identif
agerel
intersubject
differ
postvaccin
reactogen
event
immun
respons
molecular
signatur
advers
event
associ
common
bcell
phenotyp
network
antibodi
characterist
link
protect
immun
system
serolog
integr
common
signatur
observ
differ
popul
adjuv
antigen
aid
identif
novel
biomark
vaccin
efficaci
safeti
support
mechanist
data
anim
model
guid
antigenadjuv
select
given
target
popul
well
develop
novel
adjuv
latter
relev
context
acceler
develop
vaccin
lmic
amongst
other
sinc
omic
technolog
use
monitor
occurr
common
signatur
allow
smallerscal
clinic
trial
data
could
also
help
introduc
adapt
clinic
trial
design
multipl
vaccin
formul
regimen
sever
hypothes
screen
promis
arm
expand
phase
efficaci
studi
moreov
applic
technolog
human
challeng
studi
present
potenti
power
method
identifi
elucid
correl
andor
immunolog
pathway
associ
protect
approach
follow
context
vaccin
malaria
influenza
rsv
current
develop
pertussi
imi
consortium
periscop
final
multiplex
highthroughput
affin
separ
cell
protein
interest
enabl
fast
isol
effect
specif
antibodi
rare
b
cell
plasma
cell
vaccine
may
aid
identif
biomark
certain
antibodydirect
effector
function
could
guid
earlyphas
strategi
support
design
laterphas
trial
effort
need
fulfil
grow
demand
nextgener
vaccin
novel
vaccin
design
emerg
pathogen
new
indic
realiz
sustain
busi
model
support
balanc
portfolio
strengthen
intern
collabor
continu
innov
technolog
acceler
design
develop
manufactur
allow
gradual
shift
streamlin
profit
vaccin
product
significantli
contribut
global
effort
prevent
infecti
diseas
protect
vulner
popul
obtain
rapid
respons
futur
outbreak
shape
global
health
author
contribut
develop
manuscript
gave
final
approv
submiss
agre
account
aspect
work
author
declar
follow
conflict
rr
eh
employe
sharehold
gsk
group
compani
strongli
boost
prefus
specif
neutral
respons
cattl
preexpos
bovin
rsv
nat
commun
author
demonstr
even
singl
immun
nonadjuv
prefus
rsv
f
antigen
postfus
f
antigen
abl
boost
rsv
neutral
respons
relev
bovin
cattl
model
